Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
romidepsin + poly ICLC + radiation therapy
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous, Radiation
01
Overview
This therapeutic regimen is a novel multimodality immuno-chemotherapy platform being investigated by NYU Langone Health for the treatment of advanced mycosis fungoides and other cutaneous T-cell lymphomas (CTCL). The combination consists of the histone deacetylase (HDAC) inhibitor romidepsin, the Toll-like receptor 3 (TLR3) agonist poly ICLC (an immunostimulatory biologic), and focal lesional radiation. The regimen is designed to leverage the epigenetic effects of romidepsin to sensitize cancer cells, the immune-priming capabilities of poly ICLC to activate the innate immune system, and the potential abscopal effect of localized radiation to induce immunogenic cell death and systemic anti-tumor immune responses. It is primarily evaluated in patients with relapsed or refractory disease.
- Other names
- poly ICLC-NYU Langone Health-mycosis fungoidesRomidepsin + Poly ICLC + Focal RadiationRomidepsin, Poly ICLC, and radiation in advanced CTCL
02
Targets
TLR3 (Toll-like receptor 3)DNAHDAC (HDAC family)
Beyond the preview
Go deeper on romidepsin + poly ICLC + radiation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on romidepsin + poly ICLC + radiation therapy.